文献速递妇产影像US

西班牙10 110例妊娠队列中早孕期联合筛查对早产子痫前期的筛查效能

Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain.
PubMed 文献 · Ultrasound Obstet Gynecol · 2023-01-01

西班牙8个胎儿医学单位的前瞻性队列纳入10 110例单胎妊娠,在11+0至13+6周按FMF竞争风险模型联合母体特征、MAP、UtA-PI与PlGF筛查早产子痫前期,10%筛查阳性率下检出率为72.7%(95%CI 62.9-82.6%),以PAPP-A替代PlGF后检出率为66.5%(95%CI 55.8-77.2%)。

要点

  • 11-13周联合母体特征、MAP、UtA-PI与PlGF筛查早产子痫前期,10%筛查阳性率下检出率72.7%。
  • 以PAPP-A替代PlGF的三联试验筛查早产子痫前期效能较差,检出率66.5%。
  • 模型预测风险与实际观察发生率校准良好,斜率0.983(95%CI 0.846-1.120)。

核心结论

  • FMF竞争风险模型在西班牙人群11-13周妊娠可有效预测早产子痫前期,该方法可常规临床实施但需配合严格的审核与监测系统以维持高质量筛查。

研究设计与样本

  • 前瞻性队列研究,2017年9月至2019年12月在西班牙5个地区8个胎儿医学单位纳入10 110例单胎妊娠,于11+0至13+6周按标准化方案测量MAP、UtA-PI、血清PlGF与PAPP-A,并按FMF竞争风险模型计算足月与早产子痫前期风险。

诊断标准与关键数值

  • 联合母体特征与病史、MAP、UtA-PI及PlGF筛查早产子痫前期,在10%固定筛查阳性率下检出率为72.7%(95%CI 62.9-82.6%)。

临床应用与阅片要点

  • 作者认为该方法可常规临床实施,但应配合严格的审核与监测系统以维持高质量筛查;以PAPP-A替代PlGF的三联试验检出率为66.5%(95%CI 55.8-77.2%),筛查效能较差。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To evaluate the diagnostic accuracy of the Fetal Medicine Foundation (FMF) competing-risks model, incorporating maternal characteristics, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and placental growth factor (PlGF) (the 'triple test'), for the prediction at 11-13 weeks' gestation of preterm pre-eclampsia (PE) in a Spanish population.

METHODS: This was a prospective cohort study performed in eight fetal medicine units in five different regions of Spain between September 2017 and December 2019. All pregnant women with a singleton pregnancy and a non-malformed live fetus attending a routine ultrasound examination at 11 + 0 to 13 + 6 weeks' gestation were invited to participate. Maternal demographic characteristics and medical history were recorded and MAP, UtA-PI, serum PlGF and pregnancy-associated plasma protein-A (PAPP-A) were measured following standardized protocols. Treatment with aspirin during pregnancy was also recorded. Raw values of biomarkers were converted into multiples of the median (MoM), and audits were performed periodically to provide regular feedback to operators and laboratories. Patient-specific risks for term and preterm PE were calculated according to the FMF competing-risks model, blinded to pregnancy outcome. The performance of screening for PE, taking into account aspirin use, was assessed by calculating the area under the receiver-operating-characteristics curve (AUC) and detection rate (DR) at a 10% fixed screen-positive rate (SPR). Risk calibration of the model was assessed.

RESULTS: The study population comprised 10 110 singleton pregnancies, including 72 (0.7%) that developed preterm PE. In the preterm PE group, compared to those without PE, median MAP MoM and UtA-PI MoM were significantly higher, and median serum PlGF MoM and PAPP-A MoM were significantly lower. In women with PE, the deviation from normal in all biomarkers was inversely related to gestational age at delivery. Screening for preterm PE by a combination of maternal characteristics and medical history with MAP, UtA-PI and PlGF had a DR, at 10% SPR, of 72.7% (95% CI, 62.9-82.6%). An alternative strategy of replacing PlGF with PAPP-A in the triple test was associated with poorer screening performance for preterm PE, giving a DR of 66.5% (95% CI, 55.8-77.2%). The calibration plot showed good agreement between predicted risk and observed incidence of preterm PE, with a slope of 0.983 (95% CI, 0.846-1.120) and an intercept of 0.154 (95% CI, -0.091 to 0.397).

CONCLUSIONS: The FMF model is effective in predicting preterm PE in the Spanish population at 11-13 weeks' gestation. This method of screening is feasible to implement in routine clinical practice, but it should be accompanied by a robust audit and monitoring system, in order to maintain high-quality screening. © 2023 International Society of Ultrasound in Obstetrics and Gynecology.

来源:Ultrasound Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Cuenca-Gómez D, de Paco Matallana C, Rolle V, et al. Performance of first-trimester combined screening for preterm pre-eclampsia: findings from cohort of 10 110 pregnancies in Spain. Ultrasound Obstet Gynecol. 2023. PMID: 37099759. doi:10.1002/uog.26233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。